Prevalence and determinants of adverse events following ChAdOx1 nCoV-19 vaccination (COVISHIELD) – A retrospective cohort study among healthcare workers in central Karnataka, India
Background: India has launched COVID vaccination program on January 16, 2021 and precautionary dose (third dose) on January 10, 2022. Our study evaluated adverse events following immunization (AEFI) among healthcare workers (HCWs) following first, second, and precautionary dose of ChAdOx1 nCoV-19 (C...
Saved in:
| Main Authors: | Shubha B. Davalagi, Vaman P. Nayak, Anisha Ghose, Siddarth S. Marakatti, Eshwar S. Kasturi, Anurupa S. Maganahalli |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2023-11-01
|
| Series: | Journal of Family Medicine and Primary Care |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/jfmpc.jfmpc_176_23 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Guillain–Barré syndrome following Covishield vaccination in Telangana
by: Veeramalla N. Madhava Rao, et al.
Published: (2024-12-01) -
Widespread Arterial Thrombosis after ChAdOx1 nCov-19 Vaccination
by: Giorgio Berlot, et al.
Published: (2022-01-01) -
Persistent and robust antibody responses to ChAdOx1-S Oxford-AstraZeneca (ChAdOx1-S, Covishield) SARS-CoV-2 vaccine observed in Ugandans across varied baseline immune profiles.
by: Jennifer Serwanga, et al.
Published: (2024-01-01) -
Long-term antibody responses to COVAXIN and COVISHIELD vaccines in rheumatoid arthritis patients and healthy control population – A cross-sectional study
by: Vijaya Prasanna Parimi, et al.
Published: (2025-01-01) -
Possible side effects of ChAdOx1 nCov-19 vaccine in patients with sickle cell disease
by: Salam Alkindi, et al.
Published: (2021-09-01)